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Abstract 
Background: Artemisinin-based combination therapy (ACT) introduced in the mid-1990s has been recommended 
since 2005 by the World Health Organization as first-line treatment against Plasmodium falciparum in all endemic 
countries. In 2010, the combination dihydroartemisinin–piperaquine (DP) was recommended for the treatment of 
uncomplicated P. falciparum malaria. DP is one of the first-line treatments used by the French army since 2013.
Case presentation: A case of P. falciparum clinical failure with DP at day 20 was described in a 104 kg French soldier 
deployed in Djibouti. He was admitted to hospital for supervision of oral treatment with DP [40 mg dihydroarte-
misinin (DHA) plus 320 mg piperaquine tetraphosphate (PPQ)]. This corresponded to a cumulative dose of 4.6 mg/kg 
DHA and 37 mg/kg PPQ in the present patient, which is far below the WHO recommended ranges. No mutation was 
found in the propeller domain of the Kelch 13 (k13) gene, which is associated with artemisinin resistance in Southeast 
Asia. Pfmdr1 N86, 184F, S1034 and N1042 polymorphisms and haplotype 72–76 CVIET for the pfcrt gene were found in 
the present case. There was no evidence of resistance to DP.
Conclusion: This case confirms the risk of therapeutic failure with dihydroartemisinin–piperaquine by under-dosing 
in patients weighing more than 100 kg. This therapeutic failure with DP by under-dosing highlighted the importance 
of appropriate dosing guidelines and the need of research data (efficacy, pharmacokinetics and pharmacodynamics) 
in over-weight patient group.
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Background
Artemisinin-based combination therapy (ACT) introduced 
in the mid-1990s has been recommended since 2005 by the 
World Health Organization (WHO) as first-line treatment 
against Plasmodium falciparum in all endemic countries. 
Combined with wide-spread use of insecticide-treated bed 
nets, ACT has led to a significant reduction in malaria inci-
dence and mortality, especially in sub-Saharan Africa [1]. 
However, with 214 million cases globally leading to an esti-
mated 438,000 deaths worldwide in 2015, malaria remains 
a public health concern [2]; moreover, ACT therapeutic 
failures are increasing in Cambodia, where resistance to 
previous first-line anti-malarial drugs also first emerged 
[3]. Today, artemisinin resistance has been documented in 
Southeast Asia and must be closely monitored [4].
Clinical resistance, defined by a slow parasite clear-
ance [3], is in  vitro correlated with an increase in the 
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ring-stage survival rate after contact with artemisinin [5]. 
Recently, mutations in the propeller domain of the Kelch 
13 (k13) gene (PF3D71343700), especially the Y493H, 
R539T, I543T, and C580Y mutations, have been associ-
ated with in  vivo and in  vitro resistance to artemisinin 
in Southeast Asia P. falciparum strains [6–8]. Currently, 
these mutations have not been identified in African P. 
falciparum isolates [9–15]. K13 mutations as well as 
patients with slow clearing parasites were found in and 
some African countries (Kenya, Democratic Republic of 
Congo and Nigeria) [4]. However, there was no confirma-
tion about spreading artemisinin resistance to Africa.
Nevertheless, addressing ACT-failure requires a sys-
tematic approach, and the conclusion of drug resistance 
is based on a body of clinical and scientific arguments. 
Poor compliance (insufficient oversight or intolerance) 
and under-dosing (insufficient dosage, poor absorption, 
drug interactions or defects in drug metabolism) may 
also contribute.
In this report, a failure of dihydroartemisinin–pipe-
raquine (DP) anti-malarial treatment was identified in a 
patient weighing 104 kg.
Case presentation
A 35-year-old French soldier was deployed to Djibouti. 
He had no medical history, no recent trips except a return 
to France during summer holidays and intermittent 
observance of doxycycline (100 mg/day) malaria prophy-
laxis. He presented with fever, headaches, and diarrhoea 
for 4 days with paracetamol self-medication. His weight 
was 104 kg. His blood pressure was 143/78 mmHg, and 
his pulse rate was 84 bpm. A rapid diagnostic test (RDT) 
for malaria was positive for P. falciparum (Core Malaria™ 
pan/pv/pf, Fumouze diagnostics). Therefore, he was 
referred to a military hospital. Laboratory tests revealed a 
few abnormalities: lymphopenia (0.6 × 109/l lymphocyte 
count) and thrombocytopenia (30 × 109/l platelet count) 
without anaemia and moderate elevation in hepatic 
enzymes (ASAT 125 UI/l and ALAT 147 UI/l) and in 
bilirubin (30  µmol/l). Parasite detection in blood using 
quantitative buffy coat (QBC) was positive, and examina-
tion of thin blood smear stained by the May-Grünwald-
Giemsa method confirmed the diagnosis of P. falciparum 
infection with parasitaemia  <0.01  %. Blood and faecal 
culture were negative, as were dengue serology and NS1 
antigen detection. He met none of the clinical or biologi-
cal WHO criteria for severe P. falciparum malaria and 
was admitted to hospital for supervision of oral treat-
ment with DP [40  mg dihydroartemisinin (DHA) plus 
320 mg piperaquine tetraphosphate (PPQ); Eurartesim©; 
Sigma-Tau laboratory] at the maximal dosage of four pills 
once daily between meals for 3  days, recommended by 
the Sigma-Tau laboratory in absence of data on which to 
base a dose recommendation in patients weighing above 
100 kg. He was discharged at the third day with no more 
fever and a negative QBC test. He took the correct doxy-
cycline prophylaxis and used a bed-net. He was asymp-
tomatic at day 12 with a negative QBC test. At day 20, 
he complained of fever (38.9 °C) and diarrhoea. Labora-
tory examination revealed recurrence of P. falciparum 
with 0.5 % parasitaemia and the absence of co-infection. 
A thin blood smear found late-stage trophozoites without 
gametocytes. He was successfully cured by the standard 
oral therapeutic course of a fixed atovaquone–progua-
nil combination [atovaquone (250  mg) plus proguanil 
hydrochloride (100  mg), Malarone®], four pills during 
meals once daily for 3  days. Clinical and parasitological 
follow-up were completed at day 22, 27, and 48 without 
recurrence.
Though ACT failure is infrequent in Africa, the genome 
of the recurrent P. falciparum isolate was sequenced and 
searched for polymorphisms involved in antimalarial 
drug resistance. The k13 gene was amplified by polymer-
ase chain reaction (PCR) with the nested PCR method 
previously described [13]. The following primers were 
used for PCR: 3′ GGG AAT CTG GTG GTA ACA GC 5′ 
and 3′ CGG AGT GAC CAA ATC TGG GA 5′; 3′ GCC 
TTG TTG AAA GAA GCA GA 5′ and 3′ GCC AAG 
CTG CCA TTC ATT TG 5′. The K13 propeller gene was 
successfully sequenced, and the result was compared to 
the reference 3D7 strain. No mutation was identified in 
the propeller domain of the k13 gene. Two fragments 
of the pfmdr1 gene (P. falciparum multidrug resist-
ance 1) were also amplified according to the description 
by Wurtz et  al., revealing N86, 184F, S1034 and N1042 
alleles [16]. The pfcrt gene (P. falciparum chloroquine 
resistance transporter) was also sequenced, as previ-
ously described [17], and the 72–76 haplotype found was 
CVIET. Finally, the copy number of the two genes pfmdt 
and pftetQ, which in vitro reduced susceptibility to doxy-
cycline in Africa, was determined by finding one copy of 
pfmdt and two copies of pftetQ [18–20].
Discussion
Artemisinin derivatives clear parasitaemia more rapidly 
than all other currently available anti-malarial agents, 
including atovaquone–proguanil [21]. In 2010, DP was 
recommended by WHO [22] for the treatment of uncom-
plicated P. falciparum malaria, providing a promising 
alternative to other artemisinin-based combinations on 
the basis of its high efficacy, excellent safety profile, once-
daily dosing scheme, and prolonged post-treatment pro-
phylactic protection [23]. In the French army, DP is the 
available first-line treatment.
In this case, P. falciparum reinfection cannot be 
excluded because of the lack of comparative genome 
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sequencing between the two isolates. However, the low 
P. falciparum transmission in Djibouti [24–26] and the 
19-day delay both indicated that malaria relapse had 
occurred; this was further supported by the fact that this 
occurred despite prophylaxis, and only late trophozoite 
forms of the parasites without gametocytes appeared on 
the thin blood smear.
DP was well tolerated, and the whole course of treat-
ment was well completed. Failure more likely resulted 
from inadequate dosage, because there are no data on 
which to base a dose recommendation in patients weigh-
ing above 100  kg according to the European Medicines 
Agency (EMA) [27]. In the absence of toxicity data in 
patients weighing above 100  kg, the DP maximal dos-
age (i.e., 1280  mg/day PPQ and 160  mg/day DHA indi-
cated for body weight 75 to 100  kg) was administered. 
This corresponded to a cumulative dose of 4.6  mg/kg 
DHA and 37  mg/kg PPQ in the present patient, which 
is far below the WHO recommended ranges (6–20 mg/
kg DHA and 48–78  mg/kg PPQ) [22]. Indeed, WHO 
recommended the use of a PPQ dose of 1600  mg/day 
for body weigh above 80  kg [22]. In the literature, con-
cerns have been raised over potential DP under-dosing 
in young children [28], and the 2013 Worldwide Anti-
malarial Resistance Network (WWARN) has explored 
the relationship between weight-adjusted DP dosage 
(mg/kg) and therapeutic efficacy in a meta-analysis [23]. 
Data of 7072 patients from prospective studies investigat-
ing DP efficiency were pooled. Those without molecular 
evidence for failure or with follow-up less than 28  days 
were excluded. The primary endpoint was the PCR-
adjusted risk of P. falciparum recrudescence at the end 
of the study follow-up. Secondary endpoints included 
new P. falciparum infections, parasitological clearance 
rates, and gametocyte carriage. No patient was heavier 
than 100  kg. Twenty-eight patients weighed from 75 to 
100  kg, and the median cumulative dose in this group 
was 37.4 mg/kg (32.8–48.3) for PPQ and 4.7 mg/kg (4.1–
6.4) for DHA; these were close to the rates in the present 
patient and corresponded to 71.4  % (20/28) of patients 
below the WHO recommended dose [22]. The WWARN 
DP Study Group clearly showed that a total PPQ dose 
below 40  mg/kg predicted risk of recrudescence failure 
[23]. Additionally, in this previous study, six factors were 
reported to be associated with the risk of malaria recru-
descence with PPQ [23]. In the present case, two of these 
six factors were found: the PPQ total dose and the body 
weight.
Thus, there is much evidence that DP treatment out-
come depends on the PPQ plasma concentration. In 
DP, the artemisinin derivative DHA is responsible for a 
rapid initial reduction in parasitemia by targeting the 
parasitized erythrocytes, while PPQ is the partner drug 
that has a much longer elimination half-life to complete 
long-term parasite clearance [29]. Moreover, PPQ is of 
a lipophilic nature with a large volume of distribution 
[27]. For all of these reasons, it can assume that DP treat-
ment failure in the present case was more related to PPQ 
under-dosing.
Interestingly, similar overweight-related failures have 
been documented with atovaquone–proguanil [30, 31]. 
In a series of 347 P. falciparum—infected travellers, 
atovaquone–proguanil therapeutic failures were over-
represented among patients weighing more than 100 kg 
[3/12 in the group (100–115  kg) receiving a stand-
ard atovaquone–proguanil regimen versus 2/335 in 
patients <100 kg] [32]. These data emphasize the lack of 
an alternative validated malaria treatment in overweight 
patients.
However, clinical failure by resistance cannot be 
excluded. Multidrug resistance to DP is currently 
emerging in Cambodia, where recrudescent infections 
have increased from 15.4  % in 2011–2013 to 39  % in 
2012–2014; 84  % of treated patients presented with 
parasite clearance half-lives longer than 5  h in 2012–
2104, and 57 % were still parasitaemic at 72 h [33, 34]. 
All the C580Y k13 mutant parasites collected from 
recrudescent patients after a 3-day DP treatment were 
resistant in  vitro by PPQ survival assay [35]. DHA 
resistance is a real threat in African countries [4]. 
However, no mutation in the k13 gene was found in 
the present patient’s isolate. However, clinical failure 
by resistance cannot be excluded even if no mutations 
were identified in k13. Artemisinin failures seem not 
to be associated with k13 polymorphisms in Africa [15, 
36]. However, in the absence of in  vitro phenotyping 
(ring-stage survival assay) as well as data on parasite 
clearance rate, there was no evidence of resistance to 
artemisinin.
Decreased susceptibility or parasite resistance to arte-
misinin partner drugs has been observed in Africa, where 
single nucleotide polymorphisms in pfcrt and pfmdr1 
have been identified in recurrent infections with ACT 
partners like lumefantrine, mefloquine or amodiaquine 
[37–41]. However, there is no data currently supporting 
the involvement of the pfcrt or pfmdr1 genes in PPQ or 
DHA resistance [17, 42]. The isolate contained two cop-
ies of the pftetQ gene, suggesting that the parasites were 
resistant to doxycycline [18–20]. This result may explain 
why, even as he took doxycycline as prophylaxis after 
his treatment by dihydroartemisinin–piperaquine, the 
patient had recurrent malaria.
Conclusion
Sub-optimal dosing of either component of ACT can 
result in incomplete elimination of the parasite biomass 
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and subsequent recrudescence, both of which are impor-
tant driving forces for the selection of parasites with 
reduced drug susceptibility. ACT regimens should abso-
lutely be deployed using optimal dosing strategies to 
maximize the likelihood of rapid clinical and parasito-
logical cure, minimize transmission, and retard the onset 
and spread of resistances. Overweight patients are at 
particular risk of under-dosing. In some military units, 
the soldiers often weigh more than 90–100  kg. Should 
physicians automatically exclude the use of dihydroar-
temisinin–piperaquine as an anti-malarial treatment in 
these patients in the absence of data in patients weighing 
above 100 kg? Until studies assessing how to adapt treat-
ment are performed (increase the duration or the daily 
dose or repeat a course later), patients weighing more 
than 100 kg should be aware of the higher risk of thera-
peutic failure and should be closely monitored at least 
until day 28, and beyond if possible. This therapeutic fail-
ure with DP by under-dosing highlighted the importance 
of appropriate dosing guidelines and the need of research 
data (efficacy, pharmacokinetics and pharmacodynamics) 
in over-weight patient group.
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